Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Supernus Pharma (SUPN) Tops Q4 EPS by 5c, Revenues Miss; Offers FY21 Revenue Guidance Below Consensus
February 25, 2021 4:48 PM ESTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.57, $0.05 better than the analyst estimate of $0.52. Revenue for the quarter came in at $143.56 million versus the consensus estimate of $146.19 million.
We reported record revenues and operating earnings in 2020 based on the growth of... More
